| 2005 | A Carcinoembryonic Antigen-Secreting Adenocarcinoma Arising in Tailgut Cyst : Clinical Implications of Carcinoembryonic Antigen
| YONSEI MEDICAL JOURNAL |
| 2003 | A Case of Paraneoplastic Nephrotic Syndrome in a Patient with Ovarian Carcinoma
| YONSEI MEDICAL JOURNAL |
| 2005 | A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
| CANCER RESEARCH AND TREATMENT |
| 2011 | A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. | LUNG CANCER |
| 2021 | A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer | CLINICAL CANCER RESEARCH |
| 2021 | A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
| ANNALS OF ONCOLOGY |
| 2002 | A Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2019 | A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
| CANCER RESEARCH AND TREATMENT |
| 2006 | A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer | LUNG CANCER |
| 2023 | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
| CANCER RESEARCH AND TREATMENT |
| 2005 | A Pilot Study of Trans-Arterial Injection of 166Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma
| YONSEI MEDICAL JOURNAL |
| 2020 | A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy | INVESTIGATIONAL NEW DRUGS |
| 2013 | A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer | INVESTIGATIONAL NEW DRUGS |
| 2008 | A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features | ONCOLOGY REPORTS |
| 2021 | Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
| NPJ BREAST CANCER |
| 2020 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials | CANCER SCIENCE |
| 2023 | Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
| CANCER SCIENCE |
| 2011 | Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin | BIOMATERIALS |
| 2003 | Ad-mTERT-Δ19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific Manner | HUMAN GENE THERAPY |
| 2007 | Adenosine Tiphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer
| CANCER |
| 2009 | Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer
| ANTICANCER RESEARCH |
| 2021 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
| ANNALS OF ONCOLOGY |
| 2020 | Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial | LANCET ONCOLOGY |
| 2017 | An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
| CANCER MEDICINE |
| 2015 | Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication
| PLOS ONE |
| 2010 | Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial | LUNG CANCER |
| 2022 | Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2009 | Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC | JOURNAL OF NEURO-ONCOLOGY |
| 2023 | Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
| ONCOTARGET |
| 2001 | CD5와 Cytokeratin 7에 음성이고 Cytokeratin 13에 양성인 흉선 편평상피세포암 1예
| TUBERCULOSIS AND RESPIRATORY DISEASES |
| 2008 | Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients
| BMC CANCER |
| 2021 | Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial | LANCET ONCOLOGY |
| 2017 | Chemotherapy-induced irreversible alopecia in early breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 2023 | Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
| EUROPEAN JOURNAL OF CANCER |
| 2020 | Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib | BREAST CANCER RESEARCH AND TREATMENT |
| 2022 | Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant | CLINICAL CANCER RESEARCH |
| 2011 | Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2014 | cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
| JOURNAL OF CANCER |
| 2008 | Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2017 | Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
| PLOS ONE |
| 2006 | Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect | GENE THERAPY |
| 2011 | Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). | LAB ON A CHIP |
| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2020 | Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2015 | Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR
| YONSEI MEDICAL JOURNAL |
| 2003 | Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter
| CANCER RESEARCH AND TREATMENT |
| 2017 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study | EUROPEAN JOURNAL OF CANCER |
| 2003 | dl-VSVG-LacZ, a VSV-G epitope incorporated adenoviurs exhibit marked enhancement in gene transduction efficiency | HUMAN GENE THERAPY |
| 2015 | Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
| MEDICINE |
| 2005 | E1A/E1B 이중변이형 종양 선택적 살상 아데노바이러스의 개선된 암세포 살상 효과 및 항종양 효과
| Journal of Bacteriology and Virology |
| 2019 | Effect of primary tumor resection on overall survival in patients with stage IV breast cancer | BREAST JOURNAL |
| 2017 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
| CANCER DISCOVERY |
| 2020 | Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy | CLINICAL CANCER RESEARCH |
| 2023 | Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
